

HBT Acquired by American Regent

Torreya advised HBT on this transaction

Brea, C.A. and Shirely, N.Y., August 17, 2022

HBT Labs, Inc. ("HBT") has been acquired by American Regent, Inc., a Daiichi Sankyo Group company ("American Regent"). HBT has a pipeline of generic and 505(b)(2) pharmaceutical products that target various treatment indications including cancer and Central Nervous System (CNS) disorders.

The acquisition of HBT supports American Regent's growing product portfolio and efforts to expand into the oncology market. With the acquisition, American Regent will support the existing commercialization of HBT's authorized generic that is managed through a partner, in addition to supporting the launch of HBT's FDA approved 505(b)(2) New Drug Application providing for the use of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), lyophilized powder for reconstitution, 100 mg/vial.

Torreya advised HBT on this transaction. The deal represents Torreya's 16th transaction this year and 23rd oncology transaction in the last 5 years, highlighting the strength of our established oncology practice, deep understanding of the CDMO landscape, and ability to execute impactful deals despite more challenging market conditions.



ABOUT HBT LABS, INC.:

For more information about HBT, please see: www.hbt-labs.com

ABOUT AMERICAN REGENT, INC.:

For more information about American Regent, please see: www.americanregent.com

Deal Press Release

Torreya Contacts

BENJ GARRETT

Partner | New York Office

benj.garrett@torreya.com | +1 212.257.5807 | [BIO](#)

ALLEN LEFKOWITZ

Partner | New York Office

allen.lefkowitz@torreya.com | +1 212.257.5823 | [BIO](#)

KRYSTN HAMMOND

Vice President | New York Office

krystn.hammond@torreya.com | +1 212.257.5820 | [BIO](#)

VIVIAN XU

Vice President | New York Office

vivian.xu@torreya.com | +1 212.257.6026 | [BIO](#)

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.